Samer Ezziddin

7.3k total citations
182 papers, 4.0k citations indexed

About

Samer Ezziddin is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Samer Ezziddin has authored 182 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Radiology, Nuclear Medicine and Imaging, 91 papers in Pulmonary and Respiratory Medicine and 71 papers in Oncology. Recurrent topics in Samer Ezziddin's work include Radiopharmaceutical Chemistry and Applications (86 papers), Prostate Cancer Treatment and Research (58 papers) and Neuroendocrine Tumor Research Advances (40 papers). Samer Ezziddin is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (86 papers), Prostate Cancer Treatment and Research (58 papers) and Neuroendocrine Tumor Research Advances (40 papers). Samer Ezziddin collaborates with scholars based in Germany, United States and Switzerland. Samer Ezziddin's co-authors include Hans‐Jürgen Biersack, Hojjat Ahmadzadehfar, Amir Sabet, Florian Rosar, Fadi Khreish, Stefan Guhlke, Mark Bartholomä, Stephan Maus, Torjan Haslerud and Winfried A. Willinek and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Samer Ezziddin

168 papers receiving 3.9k citations

Peers

Countries citing papers authored by Samer Ezziddin

Since Specialization

Citations

This map shows the geographic impact of Samer Ezziddin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samer Ezziddin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samer Ezziddin more than expected).

Fields of papers citing papers by Samer Ezziddin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samer Ezziddin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samer Ezziddin. The network helps show where Samer Ezziddin may publish in the future.

Co-authorship network of co-authors of Samer Ezziddin

This figure shows the co-authorship network connecting the top 25 collaborators of Samer Ezziddin. A scholar is included among the top collaborators of Samer Ezziddin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samer Ezziddin. Samer Ezziddin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	[68Ga]Ga-FAPI-04 PET/CT in a patient with endometriosis: a potential game changer? 2025 ·European Journal of Nuclear Medicine and Molecular Imaging ·Caroline Burgard, Florian Rosar, Samer Ezziddin, (unknown), Erich‐Franz Solomayer, Matthias W. Laschke, (unknown), Mark Bartholomä	0
2	[89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [18F]PSMA-1007 Imaging 2024 ·Diagnostics ·(unknown), Caroline Burgard, (unknown), (unknown), Samer Ezziddin, Florian Rosar	1
3	[¹⁶¹Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [¹⁷⁷Lu]Lu-PSMA-617 2024 ·Theranostics ·Andrea Schaefer-Schuler, Caroline Burgard, (unknown), Stephan Maus, (unknown), (unknown), Mark Bartholomä, Tobias Stemler, Samer Ezziddin, Florian Rosar	22
4	225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy 2024 ·Clinical Nuclear Medicine ·Florian Rosar, Caroline Burgard, (unknown), (unknown), Mark Bartholomä, Stephan Maus, (unknown), Andrea Schaefer-Schuler, Samer Ezziddin	5
5	Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy 2024 ·Cancers ·Caroline Burgard, Fadi Khreish, (unknown), (unknown), (unknown), (unknown), (unknown), Andrea Schaefer-Schuler, Mark Bartholomä, (unknown), Samer Ezziddin, Florian Rosar	0
6	Safety and Efficacy of Selective Internal Radionuclide Therapy with 90Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization 2024 ·Pharmaceuticals ·(unknown), (unknown), Stefan Müeller, Samer Ezziddin, Andreas Bockisch, Hong Grafe, Jan Best, Juliane Goebel, Thorsten Pöppel, Amir Sabet	1
7	Histologically Confirmed Testicular Metastasis Revealed by [89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging 2023 ·Diagnostics ·Florian Rosar, Caroline Burgard, Johannes Linxweiler, Mathias Wagner, Samer Ezziddin	2
8	Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·Florian Rosar, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Caroline Burgard, Stephan Maus, (unknown), Mark Bartholomä, Samer Ezziddin	13
9	Radiometal Complexes as Pharmacokinetic Modifiers: A Potent ⁶⁸Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me 2023 ·Molecular Pharmaceutics ·(unknown), Caroline Burgard, (unknown), (unknown), Tobias Stemler, Stephan Maus, Florian Rosar, Martin Jung, Andreas Speicher, Samer Ezziddin, Jason P. Holland, Mark Bartholomä	1
10	Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [¹⁷⁷Lu]Lu-PSMA-617 2021 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Stephan Maus, Florian Rosar, Juri Ruf, Jason P. Holland, Samer Ezziddin, Mark Bartholomä	18
11	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE 2021 ·Pharmaceuticals ·Amir Sabet, (unknown), Joerg Thomas Bittenbring, Fadi Khreish, Frank Grünwald, H.-J. Biersack, Samer Ezziddin	2
12	Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me 2018 ·Organic & Biomolecular Chemistry ·(unknown), Jason P. Holland, Tilman Läppchen, Harald Scherer, Stephan Maus, Tobias Stemler, (unknown), Samer Ezziddin, Philipp Kurz, Mark Bartholomä	15
13	Einführung einer Asymmetrie-Skala des metabolischen Gelenkbefalls abgeleitet aus der konventionellen Skelettszintigrafie 2015 ·Nuklearmedizin - NuclearMedicine ·Samer Ezziddin, (unknown), Matthias F. Seidel, (unknown), Dagmar Wilsmann‐Theis, B Simon, H. J. Biersack, Amir Sabet	1
14	Überlebenszeit nach Iod-131-markierter Lipiodol-Therapie des hepatozellulären Karzinoms 2014 ·Nuklearmedizin - NuclearMedicine ·Hojjat Ahmadzadehfar, (unknown), Samer Ezziddin, Kai Wilhelm, Rolf Fimmers, Ulrich Spengler, H. Palmedo, Holger Strunk, H. Schild, (unknown), J. H. Risse	3
15	Klinische Ergebnisse unterschiedlicher Behandlungsoptionen der hämophilen Arthropathie des Ellenbogengelenks nach fehlgeschlagener konservativer Therapie 2014 ·Hämostaseologie ·Andreas C. Strauß, Georg Goldmann, Samer Ezziddin, Richard Placzek, Marcus Müller, Robert Pflugmacher, Johannes Oldenburg, P. Pennekamp	3
16	Kann die Peptid-Radiorezeptortherapie bei diffuser Knochenmetastasierung noch sicher angewendet werden? 2014 ·Nuklearmedizin - NuclearMedicine ·Amir Sabet, (unknown), Charlotte J. Yong‐Hing, Torjan Haslerud, Hojjat Ahmadzadehfar, Stefan Guhlke, F. Grünwald, H.-J. Biersack, Samer Ezziddin	11
17	Radioembolisation des hepatozellulären Karzinoms mit 90Y-Mikrosphären 2014 ·Nuklearmedizin - NuclearMedicine ·Amir Sabet, Hojjat Ahmadzadehfar, (unknown), Carsten H. Meyer, J.‐C. Wasmuth, Claus C. Pieper, H.-J. Biersack, Samer Ezziddin	17
18	Frühe Prädiktion des Ansprechens auf PRRT 2013 ·Nuklearmedizin - NuclearMedicine ·Samer Ezziddin, K. Reichmann, Charlotte J. Yong‐Hing, M. Damm, J. H. Risse, Hojjat Ahmadzadehfar, (unknown), Stefan Guhlke, H.-J. Biersack, Amin Sabet	8
19	Detection of chordoma recurrence by F-18 FDG-PET/CT 2012 ·Iranian Journal of radiation research ·Amir Sabet, Hojjat Ahmadzadehfar, (unknown), (unknown), A Schmiedel, H. J. Biersack, Samer Ezziddin	1
20	Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate 2003 ·Journal of Clinical Oncology ·H. Palmedo, (unknown), Peter Albers, Ingo G.H. Schmidt‐Wolf, Michaël Reinhardt, Samer Ezziddin, Alexius Joe, Roland Roedel, Rolf Fimmers, F. F. Knapp, Stefan Guhlke, Hans‐Jürgen Biersack	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact